Search Results - "clinical trial"

Refine Results
  1. 1
  2. 2

    Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study by Prayle, A.P., Hurley, M.N., Smyth, Alan R.

    Published 2012
    “…Objective To examine compliance with mandatory reporting of summary clinical trial results (within one year of completion of trial) on ClinicalTrials.gov for studies that fall under the recent Food and Drug Administration Amendments Act (FDAAA) legislation. …”
    Get full text
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Data Visualization and Visual Analytics in Clinical trials by Telladarla, Lakshmi Chaitanya

    Published 2013
    “…In clinical trials even small amounts of data is critical in shaping the successful formulation of a drug and there is an increasing demand for easy and intuitive access to the data. …”
    Get full text
  8. 8

    Systematic overview of clinical trials of antiarrhythmic drugs by Shilbayeh, Sirin

    Published 1998
    “…Although numerous clinical trials have been conducted, the value of antiarrhythmic drugs in many indications remains controversial. …”
    Get full text
  9. 9
  10. 10

    Clinical Trial Outsourcing: India's Regulatory Landscape. by Mukherjee, Anasua

    Published 2009
    “…This has substantially added to the location-advantage of the Indian Clinical Trial Market.…”
    Get full text
  11. 11
  12. 12
  13. 13
  14. 14

    Servitisation of the global pharmaceutical industry and implications for clinical trials organisations. by Howard, Megan

    Published 2014
    “…This report looks at opportunities for servitisation within the pharmaceutical industry and implications of this for clinical trials organisations.…”
    Get full text
  15. 15

    Azithromycin for Acute Exacerbations of Asthma: the AZALEA randomized clinical trial by Johnson, Sebastian L., Szigeti, Matyas, Cross, Mary, Brightling, Christopher, Chaudhuri, R., Harrison, Timothy W., Mansur, Adel, Robison, Laura, Sattar, Zahid, Jackson, David, Mallia, Patrick, Wong, Ernie, Corrigan, Christopher, Higgins, Bernhard, Ind, Philip, Singh, Dave, Thomson, Neil C., Ashby, Deborah, Chauhan, Anoop

    Published 2016
    “…DESIGN, SETTING, AND PARTICIPANTS The Azithromycin Against Placebo in Exacerbations of Asthma (AZALEA) randomized, double-blind, placebo-controlled clinical trial, a United Kingdom–based multicenter study in adults requesting emergency care for acute asthma exacerbations, ran from September 2011 to April 2014. …”
    Get full text
  16. 16

    New considerations in the design of clinical trials of acute kidney injury by Md Ralib, Azrina, Pickering, John W., Nejat, Maryam, Endre, Zoltan H.

    Published 2011
    “…The translation of promising experimental treatments to effective clinical trials has been hampered by the lack of a means to detect acute kidney injury early. …”
    Get full text
    Get full text
  17. 17

    Serious adverse event reporting in investigator-initiated clinical trials by Wallace, S., Myles, P., Zeps, Nikolajs, Zalcberg, J.

    Published 2016
    “…. • Pragmatic, investigator-initiated Phase IV clinical trials of post-marketed drugs or devices are needed to understand their role in everyday clinical practice. …”
    Get full text
  18. 18

    Stroke outcome in clinical trial patients deriving from different countries by Ali, Myzoon, Atula, Sari, Bath, Philip M.W., Grotta, James, Hacke, Werner, Lyden, Patrick D., Marler, John R., Sacco, Ralph L., Lees, Kennedy R.

    Published 2008
    “…Conclusion—We identified regional variations in index stroke severity, outcome, and mortality for patients enrolled in ischemic stroke clinical trials over the past 13 years that were not fully explained by case mix. …”
    Get full text
  19. 19
  20. 20

    Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials by Lim, Hui Xuan *, Masita, Arip, Abdul Aziz, Al-Fattah Yahaya *, Jazayeri, S. D. *, Poppema, Sibrandes *, Poh, Chit Laa *

    Published 2021
    “…Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. …”
    Get full text
    Get full text